Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.
Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.
As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.
Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.
For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.
Sera Prognostics (NASDAQ: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The presentation will take place on November 21, 2024, at 4:00 p.m. ET. President and CEO Zhenya Lindgardt will engage in a fireside chat to provide company updates and discuss recent achievements. The presentation will be available via live webcast and replay on the company's investor relations webpage.
Sera Prognostics reported its third quarter 2024 financial results, marking a revenue of $29,000, a drop from $42,000 in the same period of 2023. Operating expenses increased by 8% to $8.9 million, driven by product development and future sales initiatives. Net loss for the quarter was $7.9 million, up from $7.2 million in Q3 2023. Key activities included the analysis of the PRIME study data, an awareness campaign featuring TV programs with Dennis Quaid and Meg Ryan, and the introduction of home sample collection for PreTRM® testing. The company also launched a predictive analytics tool in beta testing and strengthened its commercial team. The transition to ambient whole blood collection aims to enhance scalability and unit economics. Sera Prognostics anticipates a sales inflection point with the publication of PRIME study results and expanded awareness of its test-and-treat strategy.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced it will release its third quarter fiscal year 2024 financial results on November 6, 2024, after market close. The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key topics. A press release with financial results will be distributed before the call. The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The presentation is scheduled for September 11, 2024, at 10:00 a.m. ET. Zhenya Lindgardt, President and CEO, will deliver a company update and discuss recent achievements.
Sera Prognostics specializes in improving maternal and neonatal health by providing innovative pregnancy biomarker information to healthcare professionals and patients. Investors and interested parties can access a live webcast of the presentation, as well as a replay, on the company's website at www.seraprognostics.com under the Investors page.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced its participation in the upcoming UBS Genomic Medicine Summit on August 13-14, 2024. The company, which focuses on improving maternal and neonatal health through innovative pregnancy biomarker information, will be represented by President and CEO Zhenya Lindgardt in a panel discussion titled 'Future of Genetic Testing – Babies and Beyond' on August 14 at 8:00 a.m. PT / 11:00 a.m. ET.
Investors and interested parties can access a live audio webcast of the discussion from the Investors page of Sera Prognostics' website. The webcast will remain archived on the site for 90 days following the event, providing an opportunity for those unable to attend live to catch up on the insights shared during the summit.
Sera Prognostics Inc. (Nasdaq: SERA) reported its Q2 2024 financial results. Key highlights include:
- Publication of positive AVERT PRETERM TRIAL results in Diagnostics journal
- Data analysis for PRIME study underway, with database lock expected mid-September
- Conditional approval from New York State for ambient whole-blood collection
- Implementation of cost-effective physician and patient education programs
Financial results:
- Q2 2024 revenue: $24,000 (down from $123,000 in Q2 2023)
- Total operating expenses: $9.3 million (20% decrease from Q2 2023)
- Net loss: $8.3 million (21% narrower than Q2 2023)
The company is focusing on expanding awareness of its PreTRM offering through multi-channel strategies and supporting the establishment of care guidelines based on test-and-treat data.
Sera Prognostics Inc. (NASDAQ: SERA), known as The Pregnancy Company®, has announced its plans to report second quarter fiscal year 2024 financial results on August 7, 2024, after market close. The company, which focuses on improving maternal and neonatal health through innovative pregnancy biomarker information, will host a conference call and live webcast at 5:00 p.m. Eastern Time on the same day.
The event will cover operational highlights, financial results, and key topics. Investors and interested parties can access the call via phone or webcast. US domestic callers should use (800) 836-8184, while international callers can dial (646) 357-8785. The webcast registration link is provided, and live audio will be available on the company's website. The webcast will be archived for one year on the Investors page.
Sera Prognostics has announced that their PreTRM® test-and-treat strategy has demonstrated significant improvements in neonatal health outcomes, as reported in the international journal Diagnostics. The AVERT PRETERM TRIAL showed an 18% reduction in severe neonatal morbidity and mortality, a 7-day reduction in the average hospital stay for neonates, a 2.48-week increase in gestational age for births before 32 weeks, and a 28-day reduction in hospital stays for neonates born before 32 weeks. These findings are significant for improving neonatal health in pregnancies previously considered low-risk. Additionally, the Data Safety and Monitoring Board has recommended stopping enrollment in the PRIME study due to meeting efficacy endpoints. Final results from this study are currently being analyzed.
Sera Prognostics (Nasdaq: SERA) has been added to the Russell 2000 and 3000 indexes following the 2024 annual reconstitution finalized on June 28, 2024. Effective today, the company joins the list of the 4,000 largest US stocks ranked by market capitalization as of April 30, 2024. Membership in the Russell 3000 Index entails automatic inclusion in the Russell 1000 or Russell 2000 indexes, along with relevant growth and value style indexes. The Russell indexes are significant benchmarks, used by investment managers and institutional investors, with $10.5 trillion in assets benchmarked as of December 2023. This inclusion marks a notable milestone for Sera Prognostics, enhancing its visibility among key financial stakeholders.
Sera Prognostics, specializing in maternal and neonatal health, announced its inclusion in the preliminary list for the Russell 2000 and Russell 3000 indexes. The Russell indexes, managed by FTSE Russell, include the top 4,000 US stocks based on market capitalization as of April 30, 2024. This inclusion is for one year and will give Sera exposure to investment managers and institutional investors who use these indexes as benchmarks, involving about $10.5 trillion in assets. Sera's President and CEO, Zhenya Lindgardt, sees this as a significant milestone in the company’s mission to enhance pregnancy-related healthcare.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
What is Sera Prognostics' main product?
Where is Sera Prognostics headquartered?
What is the mission of Sera Prognostics?
Who are some of the major investors in Sera Prognostics?
What recent financial milestone has Sera Prognostics achieved?
How does the PreTRM® Test work?
What are the benefits of the PreTRM® Test?
What strategic partnerships does Sera Prognostics have?
What are the company's future plans for expanding its product offerings?
What challenges does Sera Prognostics face?
